AMPK-dependent mechanisms but not hypothalamic lipid signaling mediates GH-secretory responses to GHRH and ghrelin
Loading...
Official URL
Full text at PDC
Publication date
2020
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Citation
Vázquez, M.J.; Novelle, M.G.; Rodríguez-Pacheco, F.; Lage, R.; Varela, L.; López, M.; Pinilla, L.; Tena-Sempere, M.; Diéguez, C. AMPK-Dependent Mechanisms but Not Hypothalamic Lipid Signaling Mediates GH-Secretory Responses to GHRH and Ghrelin. Cells 2020, 9, 1940. https://doi.org/10.3390/cells9091940
Abstract
GH (growth hormone) secretion/action is modulated by alterations in energy homeostasis, such as malnutrition and obesity. Recent data have uncovered the mechanism by which hypothalamic neurons sense nutrient bioavailability, with a relevant contribution of AMPK (AMP-activated protein kinase) and mTOR (mammalian Target of Rapamycin), as sensors of cellular energy status. However, whether central AMPK-mediated lipid signaling and mTOR participate in the regulation of pituitary GH secretion remains unexplored. We provide herein evidence for the involvement of hypothalamic AMPK signaling, but not hypothalamic lipid metabolism or CPT-1 (carnitine palmitoyltransferase I) activity, in the regulation of GH stimulatory responses to the two major elicitors of GH release in vivo, namely GHRH (growth hormone–releasing hormone) and ghrelin. This effect appeared to be GH-specific, as blocking of hypothalamic AMPK failed to influence GnRH (gonadotropin-releasing hormone)-induced LH (luteinizing hormone) secretion. Additionally, central mTOR inactivation did not alter GH responses to GHRH or ghrelin, nor this blockade affected LH responses to GnRH in vivo. In sum, we document here for the first time the indispensable and specific role of preserved central AMPK, but not mTOR, signaling, through a non-canonical lipid signaling pathway, for proper GH responses to GHRH and ghrelin in vivo.
Description
This work has been supported by grants from Ministerio de Ciencia e Innovación (CD: BFU2017-87721; MT-S: BFU2017-83934-P; ML: RTI2018-101840-B-I00); “la Caixa” Foundation (ID 100010434), under the agreement LCF/PR/HR19/52160022 (ML)), Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn). CIBERobn is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain supported by FEDER funds. Financial support from the Xunta de Galicia (Centro singular de investigación de Galicia accreditation 2019-2022-ED431G 2019/02) and the European Union (European Regional Development Fund-ERDF), is gratefully acknowledged. The research leading to these results has also received funding from the European Community’s Seventh Framework Program under grant agreements (FP7/2007-2013: n° 245009: NeuroFAST).












